3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
8
Breast Neoplasms
7
Uterine Cervical Neoplasms
6
Uterine Cervical Dysplasia
5
Persistent Infection
4
Melanoma
4
Glioblastoma
3
Carcinoma, Non-Small-Cell Lung
3
Sarcoma
2
Neuroblastoma
2
Lung Neoplasms
2
Influenza, Human
2
HIV Infections
2
Glioma
2
Condylomata Acuminata
2
Breast Neoplasms, Male
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spondylitis, Ankylosing
1
Small Cell Lung Carcinoma
1
Rheumatic Diseases
1
Recurrence
1
Psoriasis
1
Prostatic Neoplasms
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Nerve Tissue
1
Interventions
Rituximab
77
Cyclophosphamide
54
fludarabine phosphate
50
Peripheral Blood Stem Cell Transplantation
44
Mycophenolic Acid
34
Whole-Body Irradiation
33
Tacrolimus
25
Cyclosporine
23
Busulfan
22
Bortezomib
22
Dexamethasone
21
Etoposide
19
ibrutinib
18
Melphalan
17
Antilymphocyte Serum
17
Methotrexate
15
Lenalidomide
15
Filgrastim
14
Radiotherapy
12
Bendamustine Hydrochloride
12
Sirolimus
10
Calcium Dobesilate
10
Flow Cytometry
9
Everolimus
9
Cyclosporins
9
zanubrutinib
8
Alemtuzumab
7
ibritumomab tiuxetan
6
Transplantation
6
Therapeutics
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Waldenstrom Macroglobulinemia
×
Vaccines
×
Clear all
NCT02566265
2019-01-30
SHIVERING 2
Yale University
Phase 2
Completed
122 enrolled
10 charts